ALBUQUERQUE, NEW MEXICO

EquiSeq announced today that Canada has issued a patent on EquiSeq’s DNA tests for three genetic variants in horses that predispose to muscle disease. The tests are part of EquiSeq’s current DNA panel. Test results allow horse owners to better manage affected horses, and can be used to improve a breeding program to reduce the incidence of muscle disease.

This is the first patent issued to EquiSeq. The same patent remains pending before patent examiners in Australia, New Zealand, South Africa, the European Union, and the United States. A second patent is pending in the same countries.

Generatio GmbH performs EquiSeq’s DNA tests for the European Union and United Kingdom, while EquiSeq performs genetic testing for horse owners in the United States and the rest of the world outside of the EU and UK.